CSPC Pharmaceutical Group (HKG:1093) said China's National Medical Products Administration (NMPA) approved the clinical trial for its myasthenia gravis drug, according to a Friday filing with the Hong Kong bourse.
Myasthenia gravis is an autoimmune disease caused by autoantibodies directed against the neuromuscular junction. It is an mRNA-Lipid Nanoparticles (LNP)-based Chimeric Antigen Receptor (CAR)-T Cell Injection (SYS6020).
Price (HKD): $6.21, Change: $-0.020, Percent Change: -0.32%
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。